Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
General Thoracic and Cardiovascular Surgery
Published in: General Thoracic and Cardiovascular Surgery 8/2021

01-08-2021 | Adenocarcinoma of the Esophagogastric Junction | Review Article

Can we predict mediastinal lymph nodes metastasis in esophagogastric junction cancer? Results of a systematic review and meta-analysis

Authors: Mohamed Maatouk, Yacine Ben Safta, Ghassen Hamdi Kbir, Aymen Mabrouk, Anis Ben Dhaou, Sami Daldoul, Sofien Sayari, Karim Haouet, Mounir Ben Moussa

Published in: General Thoracic and Cardiovascular Surgery | Issue 8/2021

Login to get access

Abstract

Purpose

The aim of this systematic review and meta-analysis was to define clinical indicator that predicts mediastinal lymph nodes metastasis (MLNM) in patients with Esophagogastric junction cancer (EGJC) to select patient population requiring esophagectomy.

Methods

A systematic and electronic search of several electronic databases was performed up to August 2020. Studies containing information on risk factors for MLNM in patients diagnosed with EJGC and who underwent curative surgery were included.

Results

Two predictors, including undifferentiated type (OR = 1.82, 95% CI = 1.07–3.10, p = 0.03) and esophageal invasion length (EIL) (OR = 10.95, 95% CI = 6.37–18.82, p < 0.00001) were identified as significant predictors for the risk of MLNM.

Conclusion

Knowledge of the associations of these clinicopathological features with MLNM can be useful in determining operative strategy for EGJC.
Literature
1.
Han WH, Eom BW, Yoon HM, Reim D, Kim Y-W, Kim MS, et al. The optimal extent of lymph node dissection in gastroesophageal junctional cancer: retrospective case control study. BMC Cancer. 2019;19(1):719.CrossRef
2.
Greally M, Agarwal R, Ilson DH. Optimal management of gastroesophageal junction cancer. Cancer. 2019;125(12):1990–2001.CrossRef
3.
Shiraishi O, Yasuda T, Kato H, Iwama M, Hiraki Y, Yasuda A, et al. Risk factors and prognostic impact of mediastinal lymph node metastases in patients with esophagogastric junction cancer. Ann Surg Oncol. 2020;27(11):4433–40.CrossRef
4.
Kurokawa Y, Hiki N, Yoshikawa T, Kishi K, Ito Y, Ohi M, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157(3):551–5.CrossRef
5.
Peng J, Wang W-P, Yuan Y, Hu Y, Wang Y, Chen L-Q. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction adenocarcinoma. Ann Thorac Surg. 2015;100(1):263–9.CrossRef
6.
Sakaki A, Kanamori J, Ishiyama K, Kurita D, Oguma J, Daiko H. Distribution of lymph node metastases in locally advanced adenocarcinomas of the esophagogastric junction (cT2-4): comparison between Siewert type I and selected Siewert type II tumors. Langenbecks Arch Surg. 2020;405:509–19.CrossRef
7.
Fang W-L, Wu C-W, Chen J-H, Lo S-S, Hsieh M-C, Shen K-H, et al. Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. Ann Surg Oncol. 2009;16(12):3237–44.CrossRef
8.
Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19(2):677–83.CrossRef
9.
Koyanagi K, Kato F, Kanamori J, Daiko H, Ozawa S, Tachimori Y. Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type II adenocarcinoma: a retrospective single-institution study. Ann Gastroenterological Surg. 2018;2(3):187–96.CrossRef
10.
Matsuda T, Kurokawa Y, Yoshikawa T, Kishi K, Misawa K, Ohi M, et al. Clinicopathological characteristics and prognostic factors of patients with siewert type II esophagogastric junction carcinoma: a retrospective multicenter study. World J Surg. 2016;40(7):1672–9.CrossRef
11.
Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Weston BR, et al. Mediastinal nodal involvement after neoadjuvant chemoradiation for Siewert II/III adenocarcinoma. Ann Thorac Surg. 2019;108(3):845–51.CrossRef
12.
Sugita S, Kuwata T, Tokunaga M, Kaito A, Watanabe M, Tonouchi A, et al. Clinical significance of lymphatic invasion in the esophageal region in patients with adenocarcinoma of the esophagogastric junction. J Surg Oncol. 2020;122(3):433–41.CrossRef
13.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.CrossRef
14.
Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011.
15.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRef
16.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRef
17.
Ren G, Chen Y-W, Cai R, Zhang W-J, Wu X-R, Jin Y-N. Lymph node metastasis in gastric cardiac adenocarcinoma in male patients. World J Gastroenterol. 2013;19(37):6245.CrossRef
18.
Zheng Z, Yin J, Wu H-W, Li J, Cai J, Qin S-Q, et al. Explored risk factors for lymph node metastasis with Siewert II/III adenocarcinoma of the gastroesophageal junction. Anticancer Res. 2017;37(8):4605–10.PubMed
19.
Zheng Z, Shang Y, Xu R, Zhang H, Yin J, Zhang J, et al. Risk factors and prognosis in patients with adenocarcinoma of esophagogastric junction with lymph node metastasis of Siewert II/III. Int J Clin Exp Pathol. 2020;13(5):1262.PubMedPubMedCentral
20.
Batool S, Khan M, Akbar SA, Ashraf I. Risk factors and patterns of recurrence after curative resection in gastroesophageal junction adenocarcinoma. Pak J Med Sci. 2019;35(5):1276.PubMedPubMedCentral
21.
Mine S, Sano T, Hiki N, Yamada K, Kosuga T, Nunobe S, et al. Thoracic lymph node involvement in adenocarcinoma of the esophagogastric junction and lower esophageal squamous cell carcinoma relative to the location of the proximal end of the tumor. Ann Surg Oncol. 2014;21(5):1596–601.CrossRef
22.
Chen L, Wang YH, Cheng YQ, Du MZ, Shi J, Fan XS, et al. Risk factors of lymph node metastasis in 1620 early gastric carcinoma radical resections in Jiangsu Province in China: a multicenter clinicopathological study. J Dig Dis. 2017;18(10):556–65.CrossRef
23.
Dubecz A, Kern M, Solymosi N, Schweigert M, Stein HJ. Predictors of lymph node metastasis in surgically resected T1 esophageal cancer. Ann Thorac Surg. 2015;99(6):1879–86.CrossRef
24.
Jiang B, Zhou L, Lu J, Wang Y, Guo J. Predictors of lymph node metastasis and residual tumor in early gastric cancer patients after noncurative endoscopic resection: a systematic review and meta-analysis. Ther Adv Gastroenterol. 2020;13:1756284820935033.CrossRef
25.
Miyahara K, Hatta W, Nakagawa M, Oyama T, Kawata N, Takahashi A, et al. The role of an undifferentiated component in submucosal invasion and submucosal invasion depth after endoscopic submucosal dissection for early gastric cancer. Digestion. 2018;98(3):161–8.CrossRef
26.
27.
Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(1):69–83.CrossRef
28.
Kakeji Y, Yamamoto M, Ito S, Sugiyama M, Egashira A, Saeki H, et al. Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. Surg Today. 2012;42(4):351–8.CrossRef
Metadata
Title
Can we predict mediastinal lymph nodes metastasis in esophagogastric junction cancer? Results of a systematic review and meta-analysis
Authors
Mohamed Maatouk
Yacine Ben Safta
Ghassen Hamdi Kbir
Aymen Mabrouk
Anis Ben Dhaou
Sami Daldoul
Sofien Sayari
Karim Haouet
Mounir Ben Moussa
Publication date
01-08-2021
Publisher
Springer Singapore
Published in
General Thoracic and Cardiovascular Surgery / Issue 8/2021
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-021-01665-7

Other articles of this Issue 8/2021

General Thoracic and Cardiovascular Surgery 8/2021 Go to the issue

Original Article

Clinical impact and utility of positron emission tomography on occult lymph node metastasis and survival: radical surgery for stage I lung cancer

Case Report

Giant pseudoaneurysm that developed seven years after surgical repair of a postinfarction ventricular septal defect

Original Article

Surgical outcomes of pulmonary metastasectomy for head and neck cancer in the current era of advances in chemotherapy and immunotherapy

Case Report

Eustachian valve myxoma: a rare cause of Budd–Chiari syndrome

Original Article

The histological diagnosis and molecular testing of lung cancer by surgical biopsy for intrathoracic lesions

Case Report

Giant coronary sinus aneurysm misdiagnosed as an extracardiac mediastinal tumor